NASDAQ:CGEM Cullinan Therapeutics Q3 2026 Earnings Results & Report $11.12 -0.61 (-5.16%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Cullinan Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.74 versus the -$0.8435 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call7:00 AM ET Cullinan Therapeutics EPS ResultsActual EPS-$0.74Consensus EPS -$0.8435Beat/MissBeat by +$0.1035One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersCullinan Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$2 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cullinan Therapeutics Q3 2026 Earnings FAQ Did Cullinan Therapeutics beat earnings estimates for Q3 2026? Cullinan Therapeutics (NASDAQ:CGEM) reported earnings of -$0.74 per share for Q3 2026, beating the consensus estimate of -$0.8435. The report was announced on Tuesday, November 10, 2026. Cullinan Therapeutics Earnings HeadlinesCullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsNovember 10 at 7:00 AM | globenewswire.comCullinan Therapeutics to Participate in Upcoming Investor ConferencesNovember 9 at 10:00 AM | globenewswire.comMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.November 10 at 1:00 AM | Porter & Company (Ad)Cullinan Reports Phase 1b/2a Study Data For Velinotamig In SLE Patients; Stock UpNovember 9 at 8:30 AM | rttnews.comVelinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR ...November 8 at 2:20 PM | marketscreener.comMVelinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026November 8 at 10:30 AM | globenewswire.comSee More Cullinan Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cullinan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cullinan Therapeutics and other key companies, straight to your email. Email Address About Cullinan TherapeuticsCullinan Therapeutics (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells. Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases. These candidates remain investigational and are not approved treatments. Founded as Cullinan Oncology, the company adopted the name Cullinan Therapeutics in 2024 to reflect its expanded focus beyond oncology. It is headquartered in Cambridge, Massachusetts, and is led by President and Chief Executive Officer Nadim Ahmed.View Cullinan Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
